This program offers expert insights into current recommendations of care for patients with breast cancer and includes the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.

It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.

Clinicians need to understand the diverse and evolving SDOH landscape, especially as it relates to clinical trial access for individuals with metastatic breast cancer (mBC), and they need to consider potential strategies to address SDOH to ensure equitable care and improve overall outcomes for patients with mBC.

It is important for clinicians to have an understanding of the current treatment approaches, especially for disease that has progressed and also demonstrated mutations such as ESR1 and RET-fusion.

The treatment landscape of HR-positive, HER2-negative breast cancer is evolving constantly in the adjuvant as well as the metastatic settings. The decision-making process of treatment selection should involve careful consideration of the available evidence and a detailed discussion of the associated benefits and risks with patients. Staying up to date with the available treatment options is important to integrate new evidence-based data into clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.

Breast screening is performed in individuals without any signs or symptoms of breast cancer so that disease can be detected as early as possible, with the goal of decreasing the overall treatment needed and reducing morbidity and mortality rates.

As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.